Even so, we identified TNFRSF9 as a target worthy of further study and identified new biomarkers for clinical diagnosis through proteomic analysis and ELISA validation of AAA patients and healthy subjects. The gene discussed is TNFRSF9; the disease is triple-A syndrome.